Feature Exploit Technologies
[ Feature ]Exploit TechnologiesBridging the gap from Mind to MarketbyExploit Technologies(A member of A*STAR, Singapore)Exploit Technologies Pte Ltd (ETPL) – the marketing and commercialization armof A*STAR – helps make the ideas of researchers and scientists take flight. Mr BoonSwan Foo, Executive Chairman of ETPL, and his team give an insight of Exploit’sstrategy in transforming Singapore’s economy through commercializing R&D.26 Volume 12 Number 11 2008www.asiabiotech.com
[ Feature ]In terms of incubating our startupsformarket success and relevance,Exploit provides physical space, helps with officeExploit provides physical space,services, offers pre-qualified business service helps with office services, offers preproviders for HR and finance services, and act as qualified business service providersHR and finance services, and actan in-house VC to help start-ups evolve business foras an in-house VC to help start-upsplans and shape business models, raise funds, and evolve business plans and shapewhere relevant, lends itself as beta customers business models, raise funds, andwhere relevant, lends itself as betafor technology validation, and provides business customers for technology validation,and provides business leads forleads for aspiring technopreneurs.aspiring technopreneurs. Further,Exploit adopts a risk-sharing modelwith the start-ups by convertingapplications, refinements for mass part of the licensing payments intoOn Route toproduction and eactivelyBesides spinning off andn Singapore, the Agency formanagedbyExploitwithincubating start-ups and licensing ofScience, Technology and Research(A*STAR) has researchers and requirements from companies to technologies, Exploit Technologiesscientists developing technologies and ensure industry relevance. These also actively collaborates withintellectual properties across multiple companies would be given the option A*STAR research institutes, whereScience and Engineering disciplines to license the technology upon we identify new technology areasand Biomedical Research areas. On successful completion of the COT early in the research value chain tothe route to commercialization, project. We hope the COT program develop application-driven, multiA*STAR encourages researchers will encourage more start-ups to take disciplinary flagship projects anddrive these with commercializationand scientists to commercialize their flight with A*STAR technologies.F u r t h e r m o r e, o u r c o m - outcomes firmly in mind. We expectresearch and development (R&D)through licensing, spinning-off and mercialization team has been very some of the flagship projects to havedeveloping flagship projects. Exploit active in visiting companies to the potential to grow new industrialis the evangelist, actively promoting understand their needs. We also sectors.A d d i t i o n a l l y, E x p l o i tour success stories, setting processes, engage in marketing events andfacilitating and championing our trips to provide a platform for Technologies also launched thecompanies to realize the potential Exploit-IP Program(me), supportedstart-ups and networking.To market the technologies of A*STAR technologies in the by the Singapore’s Ministry of Tradefor collaboration with industry, biomedical sciences arena, and to and Industry (MTI), in March 2008.Exploit has a Commercialization partner with us in developing the The new Program aims to assistof Technology (COT) funding technologies. Over the last one year, local enterprises gain access andprogram where we invest upfront our biomedical sciences division benefit from an international pooland take development risks of up to took part in more than 20 marketing of Intellectual Property (IP) andUS 0.7 million per project. COT is events and proactively visited some technologies. Local enterprises canan internal gap funding mechanism 350 companies to engage the industry source and license new technologiesto develop product, process andfor A*STAR research institutes to players.carry out technology developmentSince 2002, COT in the service innovations to competeand refinement based on their biomedical sciences has led to in the global market place. Theinventions and proof-of-concept nine start-up licensees, including Exploit-IP Program, comprisingprototypes over a period of 3 to 12 Curiox, Veredus, Pro-T, Pro-Matrix, (a) a series of TechLicensing Fairs,months. Through the COT program, i-DNA, Genetic Exchange, Inflexion, and (b) an online exploit-IP portal,Exploit is creating a pool of market- Biotech Consulting Heidelberg and has promoted and facilitated theadoption of new technologies byready technologies for commercial Stressmarq.Iwww.asiabiotech.comVolume 12 Number 11 2008 27
[ Feature ]Singapore enterprises. It bringstogether under one roof a large andcomprehensive pool of IntellectualProperty (IP) arising from both localand overseas IP partnerships, residingwith the Program’s TechnologyPartners.To further assist local start-ups,Exploit Technologies announcedin July 2008, the introduction of anew Angel Investment Management(AIM) program. The AIM programprovides the support and facilitationto various angel groups in this partof the world to encourage angelinvestment in startups. ExploitTechnologies will provide full-timeresources into AIM, within theTechnology Transfer Network (TTN)alliance, to assist to establish bestpractices in the form of term-sheetsand review processes for Angelinvestments. In essence, AIM willprovide the following:(a) A pipeline of companiesfrom A*STAR and TTNpartners to Angel Networksin Singapore;(b) Facilitate the sharing ofbest practices on angelinvestments to encouragemore formation of Angelnetworks. Two new angelnetworks will be launchedby Oct 2008; andwould instead like to highlightthree interesting biomedical ones,namely, Veredus Laboratories PteLtd, Roche Diagnostics and GeorgThieme Verlag. Veredus Laboratories Pte LtdExploit Technologies licensed toVeredus Laboratories Pte Ltd theproprietary nucleic acid diagnosticprimers developed by A*STARGenome Institute of Singapore(GIS).With a growing number of viraloutbreaks, rapid diagnosis and proactive public health management arepre-requisites to protect the lives ofcitizens. In its early days, Singaporestart-up, Veredus, wanted to fill thisneed, starting with diagnostic kitsfor malaria, dengue and the H5N1strain of the avian influenza virus.The company faced the challengeof going beyond the limitations ofthe currently available diagnosticapproaches for the bird flu virus.It wanted to develop a test thatcould enable rapid diagnosis andconfirmation of the pathogen withinhours.To combat the deadly H5N1strain of the avian influenza virus,Veredus’ aim was to make one of theworld’s first commercially availableavian influenza diagnostic kits. InJuly 2005, Veredus achieved its goaland announced that it was ready witha kit that detects a gene specific tothe H5N1 strain within four hours.Veredus utilized the proprietarynucleic acid diagnostic primersdeveloped by the Genome Instituteof Singapore (GIS). The kit has beentested in avian samples in Vietnamand Malaysia with excellent resultsshowing no cross reactivity to otherpathogens.Veredus’ gene-based test isextremely sensitive and can be usedfor large group screening of people oranimals. The new tests can detect thevirus at a much earlier stage, allowingfor early detection and prevention ofan outbreak. This fast and accuratediagnostic test for the lethal H5N1bird flu strain is being snapped up bythe health authorities of countriesin the region and the Middle Eastwith enquiries coming from all overthe world.(c) Tap on the Angel networksto bring both funds and expertise to start-ups to enhance their business strategies and business networks.CommercializedTechnologiesWe have to date, since Exploit’sinception in 2002, granted licenceson more than 200 technologiesin both biomedical and physicalsciences. Our pipeline is strong.Of the licences that have beengranted to various companies, we28 Volume 12 Number 11 2008www.asiabiotech.com
[ Feature ]The H5N1 detection kit hasbeen successfully tested by the WorldHealth Organization (WTO). Roche DiagnosticsIn early 2003, a mysterious anddeadly flu-like disease, eventuallyknown as Severe Acute RespiratorySyndrome (SARS), plagued analarming number of countries,taking over 500 lives and infectingover 7000 individuals worldwide.Responding to the crisis, manycountries rushed to develop a SARSdiagnostic kit. The only way tocontain the spread of this deadlydisease was to have a system todetect the virus in the early stagesof infection. The SARS detectionkit could also help increase theunderstanding of the epidemiologyof SARS.South-east Asia was especiallyvulnerable to SARS as the disease wasspreading fast in Asia. Researchers atthe A*STAR Genome Institute ofSingapore (GIS) quickly determinedthe genetic code of the SARS virus in2003. Next, they moved to developprimers which could be used todiagnose the presence of the SARSvirus in clinical samples. Together withRoche Diagnostics, GIS then formedan agreement to bring together theirrespective expertise and developa SARS detection kit based onRoche’s patented polymerase chainreaction (PCR) technology. This PCRtechnology allows minute amounts ofgenetic material to be amplified intobillions of copies (i.e., to detectablelevels) in only a few hours. Finally,the SARS research product wasdeveloped after only eight weeks ofdevelopment time. Today, this kit isused in standard laboratory testing ofsuspected SARS samples throughoutthe world.The PCR technology allows fordirect detection of the causative agentwithin an hour. This is in contrast toantibody-based methods, wheredetection takes 3-4 hours and testingis only possible after 10-15 days fromthe onset of clinical symptoms. Nospecial training is needed to use thisdetection method. Georg Thieme VerlagExploit Technologies licensed toGeorg Thieme Verlag the Cerefy Atlas of Cerebral Vasculature(CACV) in 2007, and the ThreeDimensional (3D) Model of theVasculature Atlas Library (VAGM)in 2008.The human cerebral vasculatureis very complicated and variable. Tohave a complete understanding of thevasculature is time-consuming, andto get a good interpretation of theangiography scans is challenging. Toalleviate these challenges, A*STARresearchers came up with an idea tocreate a computerized interactiveatlas that provides a 3D vascularmodel and exploration tools.www.asiabiotech.comThe aim of the computerized3D model is to allow the usersto understand the humancerebrovasculature, vascular variantsand their spatial relationship fasterand easily. In 2007, an educationalsoftware, The Cerefy Atlas ofCerebral Vasculature (CACV),has been developed and licensedby Exploit Technologies to GeorgThieme Verlag, an internationalscientific and medical publisher.CACV is a powerful tool forclinicians, residents, and studentsin neuroanatomy, neuroradiology,neurosurgery, and neurology whoare learning, researching, or planningthe treatment of the brain and itsvasculature. In 2008, another licenseagreement has been signed with GeorgThieme Verlag to jointly marketthe 3D Model of the VasculatureAtlas Library (VAGM) to thirdparties. VAGM will be integratedto third party’s applications toprovide model-assisted processingand analysis of angiographic scans.The 3D interactive atlas ofcerebrovasculature, or CACV, isuseful for medical students, educators,and clinicians to better understandhuman cerebrovasculature in 3Dalong with surrounding anatomy(cum Laude (silver) award fromRSNA 2006), and get familiarizedwith vascular variants and branchingpatterns (Summa cum Laude (gold)award from ASNR 2008).While the 3D vasculatureatlas library, or VAGM, is useful fordevelopers to build model-basedvascular applications for diagnosisand treatment.Technology TransferNetwork (TTN)Twenty international leadinginstitutions in Singapore, the UnitedStates, Canada, Europe, and NewVolume 12 Number 11 2008 29
[ Feature ]Zealand have joined the global viii. AUT Innovation andTechnology Transfer Network (TTN)Enterprise (which includesto bolster the commercialization ofAUT Enterprise Limited andintellectual property (IP) assets. TheAUT Technology Park); andTTN, with the HQ in Singapore and ix. Binghamton Universityhosted by A*STAR, was launched in(State University ofFebruary 2008 with eight foundingNew York).members through an A*STAR-ledAssociate Membersinitiative.The TTN is a collaborative i. Technology Transfer Tactics(global publication andalliance of technology transferoffices formed to enhance theeffectiveness of technology transferto industry. The core activities of theTTN include IP cluster mapping,training and certification of TTOprofessionals, joint marketing andevents, technology advisory services,industry collaboration, and regulardialogue and sharing of bestpractices.thought leader on techtransfer best practices);ii. Motorola; andiii. Imprimatur Capital (globalearly-stage tech investmentfirm).To date, the team at Exploit ismanaging close to 3,000 activeapplications and patents coveringmore than 1,000 technologies.To date, the members include:Founding Membersi. A*STAR ExploitTechnologies;ii. Nanyang Polytechnic;iii. Nanyang TechnopreneurshipCentre;iv. Ngee Ann Polytechnic;v. Republic Polytechnic;vi. Singapore Polytechnic;vii. Temasek Polytechnic; andviii. Singapore ManagementUniversity (SMU).Affiliate Membersi. CONNECT of San Diego;ii. Global CONNECT (withoperations globally);iii. Office of TechnologyAlliances (OTA), Universityof California, Irvine;iv. Larta Institute (Los Angeles);v. MaRS (of Canada);vi. British Columbia CancerAgency (BCCA);vii. INI-GraphicsNET(Germany);30 Volume 12 Number 11 2008www.asiabiotech.com
[ Feature ]About the Exploit-IP ProgramExploit had launched the Exploit-IP Program on 27 March 2008with the support from the Ministry of Trade and Industry (MTI). ThisProgram promotes and facilitates the adoption of new technologiesby Singapore enterprises through enabling them to have access andbenefits from a larger pool of Intellectual Property (IP) arising fromboth local and overseas IP partnerships. Singapore enterprises cannow look to more resources in tapping on IP and new technologies togenerate business growth.In recent years, stiff global competition has propelled manySingapore’s enterprises to look critically for innovation and IP toseed new business growth. Licensing of IP allows an enterprise toacquire new technologies with minimum research and development(R&D) risk and to accelerate the development of new productsand services to the global market. The IP and technology that thesecompanies require may not always be available within a nationalborder. A company may also not have the means to access theinternational IP or technology market directly. Very often, an enterprisemay not have an in-house team to identify and source the IP, orbe familiar with the language of IP transaction.Borderless open innovation is thus the key to gaining an edgein global competitiveness. This trend has caught on across the globe.Exploit-IP Porgram is well-positioned to give Singapore enterprisesthis much desired competitive edge as it allows more companies tobenefit from the flow of international IP and new technologies.Exploit-IP Program is bolstered by a strong network of internationalTechnology Partners, spanning multi-national corporations, universitiesand established R&D institutes. This provides local enterprises witha gateway to the international IP markets. Today, Exploit-IP Programhas under its umbrella some 44 illustrious Technology Partners, dottedacross the world map in regions like Asia-Pacific, North America,Europe and the Middle East.The Exploit-IP Program comprises a series of TechLicensingFairs and an online exploit-IP portal.The TechLicensing Fairs feature the IP offerings of the TechnologyPartners in six industry clusters, namely, InfoComm& Media;Materials, Chemicals & Food Processing; Energy & Environment;Manufacturing & Logistics; Healthcare; and Electronics. The inauguralrun on InfoComm& Media was held on 27 March 2008, and the secondone on Materials, Chemicals & Food Processing took place on 25 June.The upcoming one on Energy and Environment will be conductedon 20 Nov 2008.The online exploit-IP portal (www.exploit-ip.com) is an additionalavenue through which Singapore enterprises can tap on to bringthemselves up to speed on the available IPs in the global scene. Theportal showcases the IP offerings from all Technology Partners, andgives local companies a quick overview of the available technologiesin various industry verticals. nwww.asiabiotech.comThe Honcho and StrategistMr Boon Swan Foo is the ExecutiveChairman of Exploit TechnologiesPte Ltd, the strategic marketingand commercialization arm ofSingapore’s Agency for Science,Technology and Research (A*STAR).He leads the commercialization andspin-off business and activities forA*STAR’s intellectual property andtechnologies. Under his leadership,A*STAR has accumulated a portfolioof more than 2200 active patents,150 licenses with projected revenuein excess of US 32.04 million overthe life of the licensing contracts,and a portfolio of two dozen spin-offcompanies. He has instilled in A*STARa mindset that is more attuned tocommercial and industrial needs. Hisinnovative approach had led to thedevelopment of the National Scienceand Technology Plan 2010, whichincluded the formation of multiagency Technology Scan Panels inphysical science and engineering.Volume 12 Number 11 2008 31
of A*STAR – helps make the ideas of researchers and scientists take flight. Mr Boon Swan Foo, Executive Chairman of ETPL, and his team give an insight of Exploit’s . approaches for the bird flu virus. It wanted
5 10 feature a feature b (a) plane a b 0 5 10 0 5 10 feature a feature c (b) plane a c 0 5 10 0 5 10 feature b feature c (c) plane b c Figure 1: A failed example for binary clusters/classes feature selection methods. (a)-(c) show the projections of the data on the plane of two joint features, respectively. Without the label .
SOLIDWORKS 2020 Basic Tools l Basic Solid Modeling - Extrude Options 3-3 (Base) A. First, the Parent feature . is created. B. Next, the Boss feature, which is a child, is created. Feature 2 (Boss) Feature 1 Feature 3 (Cut/Hole) Feature 4 (Fillet) The sample part below has 1 Parent feature (the Base) and 3 Child features
Engineering, Michigan State University, East Lansing, MI 48824-1226, USA Email {soodadit, enbody}@cse.msu.edu ABSTRACT Browser exploit packs have been increasingly used for spreading malware. They use the browser as a medium to infect users. This paper analyses the BlackHole exploit pack, and sheds light on the tactics used to distribute .
Lab Exercise – Introduction to the Metasploit Framework Objectives In this lab exercise you will complete the following tasks: Use MSF in Browser Mode to exploit Windows 2000’s RPC DCOM Add User vulnerability Use MSF in Terminal Mode to exploit the Bind-Shell overflow vulnerability. Use a new exploit to launch the attack.
How FFmpeg works HTTP Live Streaming Exploit 1 Exploit 2 (better version) . Exploit N Conclusion. Background dozens of video formats hundreds of video/audio codecs different bitrates, resolutions, etc. FFmpeg
the exploit generation technique against smart contracts and developers could leverage our tool to build more secure code. In summary, we make the following contributions: 1)We summarized two major challenges, Unsolvable Con-straints and Blockchain Effects, in smart contract exploit
1. Download public exploit code 2. Add support for iOS modified shellcode . bling! Attack only worked on Jailbroken iOS 4.2.1 (5.1 current) Attack only worked on Android 2.0 / 2.1 (6.6%) App 1 App2 App 3 Kernel Drivers App 1 App2 App 3 Kernel Drivers. CrowdStrike Exploit Walkthrough . - Was already
Exploit Protection on Windows XP AV-TEST 2014 1 Exploit Protection on Windows XP . Kingsoft Antivirus 2013 2013.SP7.5.042815 Norton Internet Security 2014 21.2.0.38 Qihoo 360 Internet Security 9 Beta 9.7.0.1001 Beta Tencent PC Manager 8.5.24996.501 Table 1: Tested Products
